Tzield Approved for Stage 3 T1D in the U.S.
What’s Happening? In an exciting update for the type 1 diabetes (T1D) community, Tzield—the first disease-modifying therapy approved by the FDA to delay progression of stage 2 T1D—has now been approved by the FDA for use in stage 3 T1D. People aged 8-17 with stage 3 T1D will soon be able to get Tzield in clinics (with a prescription) if […]
ADA 2026 Recap: Days 3 and 4
ADA’s 86th Scientific Sessions This event is one of the largest diabetes conferences in the world, bringing together over 11,000 attendees to share and learn about cutting-edge research and advancements toward cures. Each year, Breakthrough T1D-funded researchers highlight their work, demonstrating the progress we’re making toward achieving our mission. Leading experts will present over 100 […]
ADA 2026 Recap: Days 1 and 2
ADA’s 86th Scientific Sessions This event is one of the largest diabetes conferences in the world, bringing together over 11,000 attendees to share and learn about cutting-edge research and advancements toward cures. Each year, Breakthrough T1D-funded researchers highlight their work, demonstrating the progress we’re making toward achieving our mission. Leading experts will present over 100 […]
C-peptide: Everything You Need to Know
It was identified in the late 1960s. Since then, studies have shown that it is a biomarker for beta cell function. In other words, it’s a measure of beta cell health and insulin production. If it’s low (or you have none), it indicates that your pancreas is producing little or no insulin. There was even […]
Tzield Approved for Children Ages One and Older in Stage 2 T1D
What’s happening? The U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) for use in children in stage 2 type 1 diabetes (T1D) ages one and older. This is a huge win for the T1D community! Breakthrough T1D applauds the FDA for this approval and Sanofi for their commitment to new therapies for the T1D […]
Disease-Modifying Therapies and DIAGNODE-3 Update
Breakthrough T1D is focused on developing drugs, or disease-modifying therapies (DMTs), that change the course of T1D for everyone affected by it—and those yet to be. That means slowing or halting the progression of the disease, preventing it from ever occurring, and reversing it entirely through immune therapies and beta cell therapies. Note: To enlarge the image below, left click […]
Changing the Course of Type 1 Diabetes
Tzield is the first approved disease-modifying therapy for type 1 diabetes, but Breakthrough T1D will make sure it’s not the last.
See Medical Affairs. See T1D.
Closing the gap between access to and adoption of type 1 diabetes therapies is a mission priority. Chris Dunn represents these efforts in action.
Two new trials investigating baricitinib to delay T1D
What’s happening? Earlier today, Eli Lilly and Company announced that they are launching two new clinical trials for baricitinib in type 1 diabetes (T1D). These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Read on to learn more about the trials, why this […]
Tzield receives voucher for expedited review in stage 3 T1D
This past week, the FDA and Sanofi, the maker of Tzield, made an important announcement. Tzield, the first disease-modifying therapy approved for delaying onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D, has been accepted into the FDA Commissioner’s National Priority Voucher (CNPV) program for people with stage 3 T1D. […]
